Seegene Develops World’s First Multiplex MDx Assays with AI System
By LabMedica International staff writers Posted on 09 Jan 2018 |
Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).
Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.
"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."
"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."
The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.
"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."
"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics